hesperidin

Overview

Hesperidin is a naturally occurring flavonoid glycoside, best known as a citrus-derived phenolic compound. Chemically, it belongs to the flavanone class and is commonly discussed in the context of plant secondary metabolism, antioxidant chemistry, and bioactive food constituents. In biomedical research, hesperidin is of interest because it has been investigated for potential antioxidant, anti-inflammatory, and anticancer-related properties, as well as for its ability to interact with molecular targets relevant to disease pathways.

Recent studies have positioned hesperidin as both a phytochemical marker in plant and food analysis and as a candidate therapeutic payload or target-interacting ligand in experimental drug-delivery systems. In the publications provided, it was examined in relation to breast cancer therapy, colorectal cancer cell models, and nanotechnology-based delivery platforms, with molecular docking and simulation work suggesting favorable interactions with the checkpoint kinase 1 (Chk1) protein. It has also been quantified in citrus and other plant extracts using chromatographic and mass spectrometric methods, reflecting its importance in phytochemical profiling.

Focus of Latest Publications

Recent investigations of hesperidin have focused on its anti-inflammatory potential, cancer therapeutic applications, and optimization through advanced formulation strategies. In anti-inflammatory research, hesperidin was evaluated through integrated in vitro, in vivo, and in silico approaches, demonstrating its ability to inhibit reactive oxygen species (ROS) production and neutrophil degranulation in isolated human neutrophils. In vivo studies using xylene-induced ear edema and carrageenan-induced peritonitis models in rats confirmed substantial reductions in inflammation and neutrophil infiltration, with efficacy comparable to aspirin. Molecular docking analyses revealed strong predicted binding affinities of hesperidin for key inflammatory mediators including NADPH oxidase subunits, cyclooxygenases-1 and -2, p38 MAPK, and NF-κB, suggesting multiple complementary mechanisms of action.

Cancer therapy has emerged as a major research focus, with two distinct therapeutic strategies employing hesperidin. In one approach, hesperidin was formulated into liposomal nanoparticles and targeted toward Chk1 kinase, a regulator frequently overexpressed in breast cancer. The liposomal formulation overcame hesperidin's inherent solubility limitations and demonstrated potent cytotoxicity against MCF-7 breast cancer cells with an IC50 of 13.52 μg/mL, while also inhibiting angiogenesis and reducing tumor burden in a chemically-induced rat breast cancer model. In a complementary approach, hesperidin was incorporated into calcium peroxide-based self-propelled nanomotors coupled with copper nanoparticles and catalase, designed to trigger cuproptosis and ROS-mediated tumor cell death through synergistic mechanisms in acidic tumor microenvironments.

antioxidant properties have been thoroughly characterized across multiple natural sources. Hesperidin was identified as a key constituent in Bellis annua extracts and a Korean lemon cultivar ('Jeramon'), where it contributed significantly to radical-scavenging activities measured by DPPH, ABTS, ferric reducing antioxidant power, and metal-chelation assays. In the plant extract studies, hesperidin-enriched preparations were also associated with enzyme inhibition activities targeting acetylcholinesterase, α-amylase, and Tyrosinase, with correlation analyses supporting flavonoid-mediated antioxidant mechanisms.

Advanced delivery formulations have been developed to enhance hesperidin's therapeutic reach and bioavailability. Mannose-decorated N-succinyl chitosan nanoparticles encapsulating hesperidin, when embedded in a polymeric film containing sodium alginate, polyvinyl alcohol, and hyaluronic acid, demonstrated 96.31% drug entrapment efficiency and 3-fold higher skin penetration compared to free hesperidin in ex vivo studies. In an in vivo wound healing model using Wistar rats, this nanoparticle film system achieved 97.89% wound contraction by day 14, accompanied by marked collagen deposition and rapid re-epithelialization, demonstrating hesperidin's utility in promoting tissue regeneration through its documented angiogenic, antioxidant, and anti-inflammatory properties.

Key Publications

NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42324976)
Jun Chk1-Targeted Hesperidin Liposomes for Breast Cancer Therapy: An Integrated In Silico, In Vitro, and In Vivo Evaluation. (ACS applied bio materials, 2026, PMID 42166124): "Based on the molecular docking, absorption, distribution, metabolism, excretion, and toxicity profiling and molecular dynamics simulations, hesperidin (NP621) interacted with important Chk1 residues, demonstrated good stability over 800 ns, and had a favorable binding energy of -9.6 kcal/mol."
May CaO2-Powered Nanomotors with Enhanced Cellular Uptake and Lysosomal Escape for Cuproptosis and Reactive Oxygen Species-Mediated Synergistic Cancer Therapy. (ACS applied materials & interfaces, 2026, PMID 42126988): "This nanomotor is engineered by incorporating Cu-based nanoparticles into functionalized CaO2 nanoparticles, followed by Hesperidin loading for systematic tumor therapy."
May Integrated Phytochemical Profiling and Multifunctional Bioactivities of Bellis annua Extracts Obtained by Distinct Extraction Techniques. (ChemistryOpen, 2026, PMID 42012914): "LC-electrospray ionization-mass spectrometry (ESI-MS)/MS profiling enabled the quantification of major phenolic compounds, including chlorogenic acid, hyperoside, hesperidin, and several hydroxycinnamic acids, revealing extraction-dependent variations in phenolic distribution."
May Insights into the flavonoid composition and antioxidant activity of Jeramon, a novel Korean lemon cultivar. (Food chemistry, 2026, PMID 41875772): "LC-MS/MS and HPLC/PDA analyses identified a distinctive flavonoid profile enriched in eriocitrin, rutin, and hesperidin, with hesperidin remaining stable during maturation."
Jun Biomedical publication details. (PubMed Database, 2026, PMID 41846094)